Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome

scientific article published on 13 July 2016

Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S12026-016-8812-Z
P698PubMed publication ID27406736

P50authorMara TaraborelliQ56479030
Laura AndreoliQ61806166
Angela TincaniQ73304219
Amelia RuffattiQ92104506
Marta TonelloQ114417398
Pier Luigi MeroniQ38544871
Vittorio PengoQ42778559
P2093author name stringRajesh Kumar
Lorenza Maria Argolini
Maria Gerosa
Antonia Calligaro
Entela Nuri
P2860cites workDoes hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?Q68556883
The efficacy of antimalarials in systemic lupus erythematosusQ71523954
Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?Q72345769
Antimalarial agents: closing the gate on Toll-like receptors?Q79158393
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?Q80484528
APS--more systemic disease than SLEQ81398865
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodiesQ83389363
The anticardiolipin syndromeQ93670719
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Q28292418
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patientsQ33412915
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohortQ33871715
Antiphospholipid Syndrome Clinical Research Task Force reportQ34163321
Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodiesQ35928782
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysisQ36747001
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayersQ36843689
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosusQ37158591
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patientsQ37803363
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosusQ38446538
Hydroxychloroquine treatment of rheumatoid arthritisQ39531636
Clinical course of high-risk patients diagnosed with antiphospholipid syndromeQ39934417
Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.Q40877489
The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.Q40903111
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.Q41109148
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic eventsQ41911950
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohortQ41917167
Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapyQ41919785
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts)Q41931569
On the inhibitory effect of chloroquine on blood platelet aggregationQ41935192
Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trialQ41936586
Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding TQ41936680
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosusQ41942545
Metabolism of chloroquine and hydroxychloroquine in albino and pigmented ratsQ41942733
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipidsQ41943371
Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signalingQ41944676
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.Q43417859
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patientsQ44830352
Biochemical characterization of ADP-ribose polymer metabolism in SLE.Q51031046
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.Q53190445
P433issue1
P407language of work or nameEnglishQ1860
P921main subjecthydroxychloroquineQ421094
P304page(s)17-24
P577publication date2016-07-13
P1433published inImmunologic ResearchQ15754981
P1476titleLong-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome
P478volume65

Reverse relations

cites work (P2860)
Q96304889An update on the management of antiphospholipid syndrome
Q94940476Antiphospholipid Syndrome
Q58602902Antiphospholipid syndrome: state of the art on clinical practice guidelines
Q55479438Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis.
Q64101902Cerebellar Atrophy and Neurocognitive Disorder as Primary Presentation of Antiphospholipid Syndrome in a Young Male
Q47982275Diagnosis and management of the antiphospholipid syndrome
Q98181529Management of anticoagulant-refractory thrombotic antiphospholipid syndrome
Q89603158Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Q89986376Pediatric APS: State of the Art
Q88203849Role of environmental factors in autoimmunity: pearls from the 10th international Congress on autoimmunity, Leipzig, Germany 2016
Q88399624The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository
Q94672281The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Q93020058The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS
Q88930539Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment
Q33443797Thrombosis and antiphospholipid antibody syndrome during acute Q fever: A cross-sectional study
Q64086736Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
Q52654857Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Search more.